Table 4.
Univariate and multivariate Cox proportional hazard analysis of APLN expression and PFS for patients with cervical cancer in the TCGA cohort.
| Characteristics | Total (N) | HR (95% CI) univariate analysis | p Value univariate analysis | HR (95% CI) multivariate analysis | p Value multivariate analysis |
|---|---|---|---|---|---|
| N stage (N1 vs N0) | 193 | 1.983 (0.986–3.990) | 0.055 | ||
| Clinical stage (stage II, stage III and stage IV vs stage I) | 297 | 1.308 (0.821–2.084) | 0.258 | ||
| Radiation therapy (yes vs no) | 304 | 1.288 (0.754–2.200) | 0.354 | ||
| Histological type (squamous vs adenosquamous cell carcinoma) | 304 | 0.778 (0.433–1.397) | 0.400 | ||
| Menopause status (post vs pre and peri) | 231 | 1.091 (0.640–1.861) | 0.749 | ||
| Histologic grade (G3 and G4 vs G1 and G2) | 272 | 1.594 (0.967–2.627) | 0.067 | ||
| Age (>50 vs ≤50) | 304 | 1.612 (1.012–2.568) | 0.044 a | 1.174 (0.688–2.002) | 0.557 |
| PIK3CA status (Mut vs WT) | 286 | 0.994 (0.589–1.679) | 0.983 | ||
| Primary therapy outcome (PD, SD, and PR vs CR) | 217 | 7.907 (4.631–13.500) | <0.001 a | 7.461 (4.342–12.821) | <0.001 a |
| Race (Asian and Black or African American vs White) | 259 | 1.066 (0.553–2.057) | 0.848 | ||
| APLN (high vs low) | 304 | 1.683 (1.045–2.709) | 0.032 a | 1.741 (1.010–2.999) | 0.046 a |
CI: confidence interval; CR: complete response; HR: hazard ratio; PD: progressive disease; PR: partial response; SD: stable disease.
a
Statistically significant.